Cargando…
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
OBJECTIVES: We characterized pairwise and higher order patterns of non-nucleoside reverse transcriptase inhibitor (NNRTI)-selected mutations because multiple mutations are usually required for clinically significant resistance to second-generation NNRTIs. PATIENTS AND METHODS: We analysed viruses fr...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882873/ https://www.ncbi.nlm.nih.gov/pubmed/20462946 http://dx.doi.org/10.1093/jac/dkq140 |
_version_ | 1782182211437461504 |
---|---|
author | Reuman, Elizabeth C. Rhee, Soo-Yon Holmes, Susan P. Shafer, Robert W. |
author_facet | Reuman, Elizabeth C. Rhee, Soo-Yon Holmes, Susan P. Shafer, Robert W. |
author_sort | Reuman, Elizabeth C. |
collection | PubMed |
description | OBJECTIVES: We characterized pairwise and higher order patterns of non-nucleoside reverse transcriptase inhibitor (NNRTI)-selected mutations because multiple mutations are usually required for clinically significant resistance to second-generation NNRTIs. PATIENTS AND METHODS: We analysed viruses from 13 039 individuals with sequences containing at least one of 52 published NNRTI-selected mutations, including 1133 viruses from individuals who received efavirenz but no other NNRTI and 1510 viruses from individuals who received nevirapine but no other NNRTI. Of the 17 reported etravirine resistance-associated mutations (RAMs), Y181C/I/V, L100I, K101P and M230L were considered major based on published in vitro susceptibility data. RESULTS: Efavirenz preferentially selected for 16 mutations, including L100I (14% versus 0.1%, P < 0.001), K101P (3.3% versus 0.4%, P < 0.001) and M230L (2.8% versus 1.3%, P = 0.004), whereas nevirapine preferentially selected for 12 mutations, including Y181C/I/V (48% versus 6.9%, P < 0.001). Twenty-nine pairs of NNRTI-selected mutations covaried significantly, including Y181C with seven other mutations (A98G, K101E/H, V108I, G190A/S and H221Y), L100I with K103N, and K101P with K103S. Two pairs (Y181C + V179F and Y181C + G190S) were predicted to confer >10-fold decreased etravirine susceptibility. Seventeen percent of sequences had three or more NNRTI-selected mutations, mostly in clusters of covarying mutations. Many clusters had Y181C plus a non-major etravirine RAM; few had more than one major etravirine RAM. CONCLUSIONS: Although major etravirine RAMs rarely occur in combination, 2 of 29 pairs of covarying mutations were associated with >10-fold decreased etravirine susceptibility. Viruses with three or more NNRTI-selected mutations often contained Y181C in combination with one or more minor etravirine RAMs; however, phenotypic and clinical correlates for most of these higher order combinations have not been published. |
format | Text |
id | pubmed-2882873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28828732010-06-10 Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations Reuman, Elizabeth C. Rhee, Soo-Yon Holmes, Susan P. Shafer, Robert W. J Antimicrob Chemother Original Research OBJECTIVES: We characterized pairwise and higher order patterns of non-nucleoside reverse transcriptase inhibitor (NNRTI)-selected mutations because multiple mutations are usually required for clinically significant resistance to second-generation NNRTIs. PATIENTS AND METHODS: We analysed viruses from 13 039 individuals with sequences containing at least one of 52 published NNRTI-selected mutations, including 1133 viruses from individuals who received efavirenz but no other NNRTI and 1510 viruses from individuals who received nevirapine but no other NNRTI. Of the 17 reported etravirine resistance-associated mutations (RAMs), Y181C/I/V, L100I, K101P and M230L were considered major based on published in vitro susceptibility data. RESULTS: Efavirenz preferentially selected for 16 mutations, including L100I (14% versus 0.1%, P < 0.001), K101P (3.3% versus 0.4%, P < 0.001) and M230L (2.8% versus 1.3%, P = 0.004), whereas nevirapine preferentially selected for 12 mutations, including Y181C/I/V (48% versus 6.9%, P < 0.001). Twenty-nine pairs of NNRTI-selected mutations covaried significantly, including Y181C with seven other mutations (A98G, K101E/H, V108I, G190A/S and H221Y), L100I with K103N, and K101P with K103S. Two pairs (Y181C + V179F and Y181C + G190S) were predicted to confer >10-fold decreased etravirine susceptibility. Seventeen percent of sequences had three or more NNRTI-selected mutations, mostly in clusters of covarying mutations. Many clusters had Y181C plus a non-major etravirine RAM; few had more than one major etravirine RAM. CONCLUSIONS: Although major etravirine RAMs rarely occur in combination, 2 of 29 pairs of covarying mutations were associated with >10-fold decreased etravirine susceptibility. Viruses with three or more NNRTI-selected mutations often contained Y181C in combination with one or more minor etravirine RAMs; however, phenotypic and clinical correlates for most of these higher order combinations have not been published. Oxford University Press 2010-07 2010-05-12 /pmc/articles/PMC2882873/ /pubmed/20462946 http://dx.doi.org/10.1093/jac/dkq140 Text en © The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy http://creativecommons.org/licenses/by-nc/2.0/uk/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Reuman, Elizabeth C. Rhee, Soo-Yon Holmes, Susan P. Shafer, Robert W. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
title | Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
title_full | Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
title_fullStr | Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
title_full_unstemmed | Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
title_short | Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
title_sort | constrained patterns of covariation and clustering of hiv-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882873/ https://www.ncbi.nlm.nih.gov/pubmed/20462946 http://dx.doi.org/10.1093/jac/dkq140 |
work_keys_str_mv | AT reumanelizabethc constrainedpatternsofcovariationandclusteringofhiv1nonnucleosidereversetranscriptaseinhibitorresistancemutations AT rheesooyon constrainedpatternsofcovariationandclusteringofhiv1nonnucleosidereversetranscriptaseinhibitorresistancemutations AT holmessusanp constrainedpatternsofcovariationandclusteringofhiv1nonnucleosidereversetranscriptaseinhibitorresistancemutations AT shaferrobertw constrainedpatternsofcovariationandclusteringofhiv1nonnucleosidereversetranscriptaseinhibitorresistancemutations |